Twist Bioscience (NASDAQ:TWST) PT Lowered to $43.00

Twist Bioscience (NASDAQ:TWSTGet Rating) had its price target reduced by Barclays from $45.00 to $43.00 in a research report report published on Monday, The Fly reports. They currently have an overweight rating on the stock.

Several other equities analysts have also recently issued reports on TWST. Robert W. Baird lifted their price objective on Twist Bioscience from $43.00 to $56.00 in a research note on Monday, August 8th. SVB Leerink decreased their price objective on Twist Bioscience from $45.00 to $30.00 and set a market perform rating for the company in a research note on Monday.

Twist Bioscience Stock Performance

Shares of TWST opened at $25.53 on Monday. The stock has a 50-day simple moving average of $32.37 and a 200-day simple moving average of $36.79. The stock has a market capitalization of $1.44 billion, a PE ratio of -6.33 and a beta of 1.15. Twist Bioscience has a 1 year low of $23.90 and a 1 year high of $99.74.

Insider Buying and Selling

In related news, SVP Paula Green sold 8,514 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $37.43, for a total transaction of $318,679.02. Following the completion of the sale, the senior vice president now owns 14,199 shares in the company, valued at $531,468.57. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 9,211 shares of company stock worth $341,371 over the last 90 days. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its stake in Twist Bioscience by 3.3% during the third quarter. Royal Bank of Canada now owns 9,025 shares of the company’s stock worth $318,000 after purchasing an additional 291 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Twist Bioscience by 23.6% during the second quarter. Nisa Investment Advisors LLC now owns 1,570 shares of the company’s stock worth $55,000 after purchasing an additional 300 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Twist Bioscience by 12.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,023 shares of the company’s stock worth $106,000 after buying an additional 333 shares during the period. Amalgamated Bank increased its position in Twist Bioscience by 4.4% during the first quarter. Amalgamated Bank now owns 8,677 shares of the company’s stock worth $428,000 after buying an additional 368 shares during the period. Finally, Captrust Financial Advisors increased its position in Twist Bioscience by 101.3% during the second quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock worth $27,000 after buying an additional 382 shares during the period.

Twist Bioscience Company Profile

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Articles

The Fly logo

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.